Photo of Mark A. Socinski, MD

Mark A. Socinski, MD

Executive Medical Director of the AdventHealth Cancer Institute, Medical Oncologist

Research Area:

Expertise of Mark A. Socinski, MD

6 items. To interact with these items, press Control-Option-Shift-Right Arrow
Biography

Dr. Mark A. Socinski is a board-certified, fellowship trained medical oncologist, specializing in all thoracic malignancies, including small cell and non-small cell lung cancers and mesothelioma. He is an internationally recognized expert in the development of novel chemotherapy agents and treatment strategies for advanced non-small cell lung cancer and small cell lung cancer. His research has focused on incorporating personalized medicine and molecular biomarkers in the treatment of lung cancer. Dr. Socinski formerly served as Co-Chair of the Thoracic Malignancies Steering Committee for the National Cancer Institute. He also serves on the Respiratory Core Committee of the Cancer and Leukemia Group B (Alliance) and has been instrumental in the development of many cooperative clinical trials. He is the Executive Medical Director of the AdventHealth Cancer Institute.

Education

University of Vermont, Burlington, VT

Residency

Harvard Medical School/Beth Israel Hospital, Boston

Fellowship

Harvard Medical School/Beth Israel Hospital, Boston, MA; Dana-Farber Cancer Institute, Boston, MA

Specialty

Medical Oncology

Board Certifications

American Board of Internal Medicine

Publications of Mark A. Socinski, MD
  • A phase I study to evaluate the safety, pharmacokinetics, and pharmacodynamics of PF-06939999 (PRMT5 inhibitor) in patients with selected advanced or metastatic tumors with high incidence of splicing factor gene mutations
    , ESMO OPEN

  • A lack of association between BMI and chemoimmunotherapy efficacy in advanced non-small cell lung cancer: Secondary analysis of the IMpower150 and IMpower130 clinical trials
    , BMC CANCER

  • A phase II clinical trial evaluating the safety and efficacy of durvalumab as first line therapy in advanced and metastatic non-small cell lung cancer patients with Eastern Cooperative Oncology Group performance status of 2
    , ECLINICALMEDICINE

    More sources loaded

  • Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non-Small Cell Lung Cancer
    , CLINICAL CANCER RESEARCH

  • Phase II Randomized Trial of Carboplatin, Pemetrexed, and Bevacizumab With and Without Atezolizumab in Stage IV Nonsquamous Non-Small-Cell Lung Cancer Patients Who Harbor a Sensitizing EGFR Mutation or Have Never Smoked
    , CLINICAL LUNG CANCER

  • Population Pharmacokinetics of MYL-1402O, a Proposed Biosimilar to Bevacizumab and Reference Product (AvastinĀ®) in Patients with Non-squamous Non-small Cell Lung Cancer
    , EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS

  • Pan-tumor survey of RET fusions as detected by next-generation RNA sequencing identified RET fusion positive colorectal carcinoma as a unique molecular subset
    , TRANSLATIONAL ONCOLOGY

  • Differential impact of EGFR exon 20 insertion location on tyrosine kinase inhibitor sensitivity
    , ANNALS OF ONCOLOGY

  • Correlation of safety and efficacy in atezolizumab therapy across indications
    , ANNALS OF ONCOLOGY

  • Safety, Tolerability, and Antitumor Activity of Zipalertinib Among Patients With Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertions
    , JOURNAL OF CLINICAL ONCOLOGY

Associated Clinical Trials for Mark A. Socinski, MD